QUOTED. 23 June 2021. Dave Marver.
Executive Summary
Onward has been granted three FDA breakthrough device designations for ARC Therapy, a spinal cord stimulation therapy that aims to restore movement and improve quality of life of people with spinal cord injuries.
“Working in concert with our research partners, we’re looking at a host of other indications that leverage our technologies, either the implantable or the external, that we are hopeful will also help people with spinal cord injury.” – Dave Marver, CEO, Onward
- Find out more: Onward Secures FDA Breakthrough Designation To Improve Movement, Quality Of Life After Spinal Cord Injuries
Click here for a free trial of Medtech Insight